| Literature DB >> 31774570 |
Martin B Delatycki1,2,3, Fowzan Alkuraya4,5,6, Alison Archibald1,2,3, Carlo Castellani7, Martina Cornel8,9, Wayne W Grody10,11, Lidewij Henneman8,9, Adonis S Ioannides12, Edwin Kirk13,14,15, Nigel Laing16,17, Anneke Lucassen18, John Massie2,3,19, Juliette Schuurmans18,20, Meow-Keong Thong21, Irene van Langen20, Joël Zlotogora22.
Abstract
Reproductive carrier screening started in some countries in the 1970s for hemoglobinopathies and Tay-Sachs disease. Cystic fibrosis carrier screening became possible in the late 1980s and with technical advances, screening of an ever increasing number of genes has become possible. The goal of carrier screening is to inform people about their risk of having children with autosomal recessive and X-linked recessive disorders, to allow for informed decision making about reproductive options. The consequence may be a decrease in the birth prevalence of these conditions, which has occurred in several countries for some conditions. Different programs target different groups (high school, premarital, couples before conception, couples attending fertility clinics, and pregnant women) as does the governance structure (public health initiative and user pays). Ancestry-based offers of screening are being replaced by expanded carrier screening panels with multiple genes that is independent of ancestry. This review describes screening in Australia, Cyprus, Israel, Italy, Malaysia, the Netherlands, Saudi Arabia, the United Kingdom, and the United States. It provides an insight into the enormous variability in how reproductive carrier screening is offered across the globe. This largely relates to geographical variation in carrier frequencies of genetic conditions and local health care, financial, cultural, and religious factors.Entities:
Year: 2019 PMID: 31774570 DOI: 10.1002/pd.5611
Source DB: PubMed Journal: Prenat Diagn ISSN: 0197-3851 Impact factor: 3.050